
The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
First-Line PARPi Maintenance in Advanced Ovarian Cancer
Case: A 54-Year-Old Female With Ovarian Cancer
H & P






